MarketCap
Facebook
X
TelegramGeschäftsbericht 2023
hinzugefügt 05.03.2024
Nektar Therapeutics EV 2011-2025 | NKTR
EV Jährlich Nektar Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 399 M | 516 M | 2.45 B | 3.78 B | 4.03 B | 7.55 B | 13.3 B | 2.06 B | 2.25 B | 2.25 B | 2.1 B | 1.4 B | 1.11 B |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 13.3 B | 399 M | 3.32 B |
EV anderer Aktien in der Pharmaeinzelhändler
| Name | EV | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
AbCellera Biologics
ABCL
|
1.01 B | $ 3.56 | -2.51 % | $ 1.05 B |  Canada |
 |
AC Immune SA
ACIU
|
82.4 M | $ 2.82 | -2.07 % | $ 229 M |  Schweiz |
 |
ADiTx Therapeutics
ADTX
|
23.1 M | $ 3.05 | 4.81 % | $ 40.2 K |  USA |
 |
Aeterna Zentaris
AEZS
|
5.52 M | - | 5.93 % | $ 314 M | Canada |
 |
Abeona Therapeutics
ABEO
|
184 M | $ 4.81 | -1.23 % | $ 103 M | USA |
 |
ARCA biopharma
ABIO
|
436 M | - | 1052.0 % | $ 415 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-9.16 M | - | - | $ 26.5 M | USA |
 |
Akouos
AKUS
|
95.1 M | - | 0.23 % | $ 488 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
1.72 B | $ 11.96 | 0.13 % | $ 3.7 B | USA |
 |
Axcella Health
AXLA
|
22.6 M | - | -16.42 % | $ 249 M | USA |
 |
Acer Therapeutics
ACER
|
38.2 M | - | 2.71 % | $ 14 M | USA |
 |
Atreca
BCEL
|
94.8 M | - | -11.76 % | $ 5.79 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
15.7 M | - | -2.5 % | $ 5.88 M | USA |
 |
argenx SE
ARGX
|
-796 M | $ 901.39 | -1.59 % | $ 25 B |  Niderland |
 |
Armata Pharmaceuticals
ARMP
|
250 M | $ 5.88 | 1.03 % | $ 212 M | USA |
 |
Achieve Life Sciences
ACHV
|
95.5 M | $ 4.69 | -1.88 % | $ 93 M | USA |
 |
BioDelivery Sciences International
BDSI
|
445 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
253 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Acorda Therapeutics
ACOR
|
-13.2 M | - | -24.86 % | $ 820 K | USA |
 |
Ascendis Pharma A/S
ASND
|
726 M | $ 206.12 | -1.18 % | $ 5 B |  Danmark |
 |
Alterity Therapeutics Limited
ATHE
|
-28.9 M | $ 3.36 | -1.95 % | $ 8.08 B |  Australia |
 |
Autolus Therapeutics plc
AUTL
|
1.11 B | $ 1.54 | -1.92 % | $ 393 M |  Britain |
 |
Acasti Pharma
ACST
|
24 M | - | 4.01 % | $ 150 M | Canada |
 |
Bellerophon Therapeutics
BLPH
|
77.1 M | - | -74.18 % | $ 955 K | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
2.15 B | - | -15.15 % | $ 60.3 M | Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.95 B | - | - | $ 40.3 B | USA |
 |
Baudax Bio
BXRX
|
29.8 M | - | 0.59 % | $ 63 K | USA |
 |
AbbVie
ABBV
|
337 B | $ 226.39 | -1.0 % | $ 400 B | USA |
 |
Cara Therapeutics
CARA
|
71.1 M | - | -3.03 % | $ 260 M | USA |
 |
CymaBay Therapeutics
CBAY
|
3.36 B | - | - | $ 3.45 B | USA |
 |
ChemoCentryx
CCXI
|
91.4 M | - | - | $ 3.74 B | USA |
 |
Codiak BioSciences
CDAK
|
281 M | - | -55.98 % | $ 2.15 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
1.47 B | $ 15.13 | -13.34 % | $ 2.23 B | USA |
 |
BioLineRx Ltd.
BLRX
|
15 M | $ 3.37 | 3.47 % | $ 908 M |  Israel |
 |
Avid Bioservices
CDMO
|
661 M | - | - | $ 789 M | USA |
 |
Biogen
BIIB
|
28.3 B | $ 182.61 | 0.35 % | $ 26.6 B | USA |
 |
Cerevel Therapeutics Holdings
CERE
|
6.84 B | - | - | $ 7.29 B | USA |
 |
ContraFect Corporation
CFRX
|
24.7 M | - | -5.16 % | $ 5.39 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
3.41 B | - | -1.52 % | $ 24.7 M | USA |
 |
Beam Therapeutics
BEAM
|
2.59 B | $ 27.45 | -5.05 % | $ 2.26 B | USA |
 |
BioMarin Pharmaceutical
BMRN
|
13.5 B | $ 53.01 | -1.51 % | $ 10.1 B | USA |
 |
BioNTech SE
BNTX
|
-6.64 B | $ 96.12 | 0.13 % | $ 27.2 B |  Germany |
 |
Clearside Biomedical
CLSD
|
122 M | - | - | $ 25.3 M | USA |
 |
Celsion Corporation
CLSN
|
20.7 M | - | -6.63 % | $ 13.9 M | USA |
 |
Clovis Oncology
CLVS
|
839 M | - | -7.23 % | $ 13 M | USA |
 |
Advaxis
ADXS
|
-3.02 M | - | -9.65 % | $ 45.9 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
11.4 M | - | - | $ 231 M | USA |
 |
Chimerix
CMRX
|
95.8 M | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
14.7 M | - | - | $ 401 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
10.2 B | $ 9.44 | -1.82 % | $ 611 M | USA |